Recently, Bacillus subtilis spores were shown to be endowed with strong adjuvant capacity when coadministered with purified antigenic proteins. In the present study we assessed whether spores possess adjuvant properties when combined with DNA vaccines. We showed that B. subtilis spores promoted the activation of dendritic cells in vitro and induced migration of pro-inflammatory cells after parenteral administration to mice. Likewise, co-administration of spores with a DNA vaccine encoding the human papillomavirus type 16 (HPV-16) E7 protein enhanced the activation of antigen-specific CD8 + T cell responses in vivo. Mice immunized with the DNA vaccine admixed with spores presented a protective immunity increase to previously implanted tumor cells, capable of expressing HPV-16 oncoproteins. Finally, we observed that the adjuvant effect can vary accordingly to the number of co-administered spores which may be ascribed with the ability to induce. Collectively, the present results demonstrate for the first time that B. subtilis spores can also confer adjuvant effects to DNA vaccines.
Introduction
Adjuvants are essential elements in the composition of most vaccine formulations, particularly in subunit vaccines such as those containing purified proteins or DNA vectors, which are naturally endowed with low immunogenicity in mammalian species, especially in humans. Notably, the repertoire of adjuvants for vaccines based on purified proteins has been significantly enlarged in the last years [1, 2] . Concerning DNA vaccines, several approaches have been tested to improve the immune responses induced in large mammalian hosts, such as in vivo electroporation [3, 4] , codon usage optimization of the antigen-encoding sequence [5] and co-administration of plasmids encoding cytokines [6] or agonists of innate immunity [7] [8] [9] . The association of DNA vaccines with particulate adjuvants, such as poly(lactic-co-glycolic) acid (PLGA) biodegradable microparticles, has been also shown to enhance the immunogenicity elicited by protein-based and DNA vaccines, which may be related to their efficient phagocytosis by antigen presenting cells (APCs) including dendritic cells (DCs) and macrophages [10, 11] .
Bacillus subtilis spores have been successfully used as a probiotic for both humans and animals [12] . Moreover, B. subtilis spores have been successfully employed as vectors for the mucosal delivery of vaccine antigens [13] [14] [15] [16] . Recently, B. subtilis have been shown to induce strong adjuvant effects after co-administration with protein antigens either admixed or adsorbed at the spore coat surface [17, 18] . Nonetheless, no information is available concerning the adjuvant effects of bacterial spores as adjuvants for DNA vaccines, particularly for the induction of cellular immune responses, an immunological hallmark of such vaccine strategy.
In the present study, we demonstrate that B. subtilis spores display dose-dependent adjuvant effects on immune responses induced in mice after parenteral administration with a DNA vaccine. As a model vaccine, we employed a DNA plasmid encoding the human papillomavirus type 16 (HPV-16) E7 oncoprotein genetically fused to the herpes simplex virus type 1 glycoprotein D (gD), previously shown to confer preventive and therapeutic anti-tumor immunity in mice [19] [20] [21] . Here we showed that B. subtilis spores are capable to promote activation of DCs and induce a migratory behavior of pro-inflammatory cell populations in mice. Furthermore, co-administration of spores increased both the activation of antigen-specific CD8 + T cells and antigen-specific antibody production. Altogether, the present evidences demonstrate that B. subtilis spores display adjuvant effects when co-administered with DNA vaccines. http://dx.doi.org/10.1016/j.vaccine.2015.03.043 0264-410X/© 2015 Elsevier Ltd. All rights reserved.
Materials and methods

Mice
Male C57BL/6 mice at 6-8 weeks of age were supplied by the Animal Breeding Center of the Biomedical Sciences Institute of the University of São Paulo and housed at the Parasitology Department of the University of São Paulo. All of the procedures involving animal handling followed the recommendations for the proper use and care of laboratory animals from the University of São Paulo Ethics Committee (protocol number 95-2011).
TC-1 cell line
The TC-1 cell line was kindly provided by Dr. T.C. Wu (John Hopkins University, Baltimore, MD, USA). This cell line is transfected with retrovirus vectors encoding v-Ha-ras, HPV-16 E6 and E7 [22] . The TC-1 cells were propagated in DMEM medium supplemented with 2 mM l-glutamine, 1 mM sodium pyruvate, 2 mM non-essential amino acids, 10 mM HEPES buffer, 50 units/ml penicillin/streptomycin, 10% fetal bovine serum (FBS) and were kept at 37 • C at 5% CO 2 . Prior to inoculation, the TC-1 cells were harvested by trypsinization, washed twice, and suspended in serum-free media at the proper cell concentration.
DNA vaccine
The DNA vaccine pgDE7h encodes the HPV-16 E7 oncoprotein genetically fused near the C terminal portion of the HSV-1 gD protein as previously described [20] . The gene sequence was cloned in the pUMVC3 vector (Aldevron, ND, USA), which contains a CMV promoter and a kanamycin resistance-encoding gene.
Preparation of spores
The sporulation of B. subtilis strain 1012 was performed by the nutrient exhaustion method [23, 24] . After 7 days of sporulation, the cultures were centrifuged at 10,000 rpm for 10 min and washed three times with distilled water. The spores were suspended in water and incubated for 1 h at 68 • C. The spores were visualized under a digital microscope EVOS ® (AMG) and titrated to determine the number of colony-forming units (CFU/ml). The heat-killed spores were obtained from autoclaving viable spores at 121 • C for 15 min.
In vivo migration of pro-inflammatory cells
Mice were inoculated intraperitoneally with 5 × 10 8 live or killed spores in 100 l of PBS. After 24 h, the peritoneal cavity was washed with 10 ml of PBS containing 2 mM EDTA and the collected cells were then incubated for 30 min at 4 • C with PElabeled anti-Gr1, FITC-labeled anti-CD11b, APC-labeled anti-F4/80 and PerCP-Cy5.5-labeled anti-Ly6C (BD Biosciences). The cells were examined by flow cytometry using a FACS Canto (BD Biosciences) and data were analyzed using the FlowJo software (TreeStar, OR, USA).
Stimulation and activation of mouse DCs in vitro
Spleens and lymph nodes from naïve C57BL/6 mice were collected and placed into a culture dish containing cold RMPI medium supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin. The spleens were carefully macerated. Large particulate matter was removed by passing the cell suspension through a cell strainer 70 m nylon membrane. Cells were washed with icecold MACS buffers (PBS, 0.5% bovine serum albumin, 2 mM EDTA) and suspended in MACS buffer. Then, cells were incubated with MicroBeads (Miltenyi Biotec) conjugated to hamster anti-mouse CD11c monoclonal antibodies according to the manufacture's protocols. Positively selected DCs contained >90% CD11c + cells. For stimulation, DC cells were incubated for 24 h in the presence of LPS (100 ng/ml), DNA (1 g of pgDE7h) or three different concentrations of live spores (2 × 10 6 , 2 × 10 7 and 2 × 10 8 ). After this period, the cells were stained with anti-CD11c, anti-I-A[b] (anti-MHCII), anti-CD40, anti-CD80 and anti-CD86 conjugated to different fluorochromes (BD Biosciences). The cells were examined by flow cytometry using FACS Fortessa (BD Biosciences) and data were analyzed using the FlowJo software (TreeStar, OR, USA). CD40, CD80 and CD86 expression values are shown from gated CD11c + MHCII + cells. Data are shown as median fluorescence intensity.
Cytometric bead array (CBA)
The cytokines levels in the supernatant of dendritic cells cultures were measured after 24 h of stimulation. The test was conducted with the CBA kit Th1/Th2/Th17 (BD Biosciences) according to the manufacturer's instructions for the quantification of IL-2, IL-4, IL-6, INF-␥, TNF-␣, IL-17A and IL-10. In summary, the sample and the cytokine kit standards were mixed with microspheres coated with capture antibodies specific for the respective cytokines. Then, samples are incubated with the detection antibody labeled with phycoerythrin (PE) for 2 h at room temperature and protected from light. The flow cytometric analysis was based on the fluorescence intensity using FACS Fortessa (BD Biosciences). The data were analyzed with the aid of the FCAP Array 3.0 to determine the concentration (pg/ml) and means of fluorescence intensities (MFI) of the samples and standards.
Enzyme-linked immunosorbent assay (ELISA)
The anti-gD, anti-E7 and anti-spores antibody titers were measured by ELISA as previously described [25] . Plates were coated with 250 ng/well of purified truncated E7 fragment (amino acid 1 to 60) or purified gD in MaxiSorp plates (Nunc). After incubation for 16 h at 4 • C, the plates were blocked with 3% gelatin in PBS and incubated at 37 • C for 2 h. Individual serum samples were added at the initial 1:10 dilution and subsequent two fold serial dilutions. Plates were kept at 37 • C for 1 h. After incubation, anti-mouse IgG conjugated to peroxidase (1:3000) was added and the reaction was later developed with a solution containing O-fenilenodiaminadihidrocloreto (OPD). The optical densities were determined at 492 nm in Epoch TM Multi-Volume Spectrophotometer (Bio Tek Instruments). All samples were assayed in duplicates and the absorbance values of control reactions (wells without serum addition) were subtracted from results obtained with the tested serum samples. Dilution curves were drawn for each sample and the titers calculated as the reciprocal values of the highest dilution with an optical density of 0.1.
Immunization and tumor cell challenge
Groups of 5 mice were challenged subcutaneously (s.c.) with 7.5 × 10 4 TC-1 tumor cells suspended in 100 l of serum-free media and injected into the right rear flank of the animals. The mice were vaccinated with one 40 g dose of the DNA vaccine (coadministered with spores or not) 3 days after the implantation of the tumor cells. The vaccine dose was applied into the tibialis anterior muscle of each mice hind limb (divided in two 50 l aliquots). Tumor growth was monitored by visual inspection and palpation three times a week for a period of 60 days. The animals were scored as tumor-bearing when the tumors reached a size of approximately 2 mm in diameter. The mice were euthanized once the tumors exceeded a diameter of 15 mm or became necrotic.
Intracellular cytokine staining
Intracellular IFN-␥ staining was performed from blood samples collected 7, 14, 21 or 28 days after the vaccine administration, according to previously described procedures [20] . The blood samples were treated for lysis of red blood cells and cultured at a concentration of 10 6 cells/well for 6 h at 37 • C in 96-well round bottom microtiter plates with 10 g/ml of Brefeldin A (GolgiPlug; BD Biosciences, CA, USA) in the presence or not of 3 g/ml of the E7-specific RAHYNIVTF peptide (amino acids 49-57) [26] . After incubation, cells were stained with FITC-conjugated anti-CD8a antibody and after fixation and permeabilization, with PE-labeled anti-IFN-␥. The buffers and antibodies were purchased from BD Biosciences (CA, USA). The cells were examined by flow cytometry using a FACS Fortessa (BD Biosciences) and data were analyzed using FlowJo software (TreeStar, OR, USA).
Statistical analyses
The ANOVA test was applied followed by Bonferroni's post-test, when individual data points were compared.
Results
B. subtilis spores promote migration of pro-inflammatory cells and DC activation in mice
Live and heat-killed spores were tested for the migration of pro-inflammatory cells after i.p. administration and subsequent identification of different migratory cell populations. As indicated in Fig. 1 , both live (LS) and heat-killed spores (KS) induced a significant influx of CD11b + and CD11b + Gr1 + cells ( Fig. 1A and C) , which may represent neutrophils, eosinophils or immature myeloid cells, also F4/80 + and F4/80 + Ly6C hi cells ( Fig. 1B and D) , corresponding to macrophages and inflammatory monocytes. No significant influx of CD19 + or CD11c + cells were detected in the peritoneal cavity of mice inoculated with B. subtilis spores (data not shown).
In addition, we determined the capacity of spores to activate mouse DCs after in vitro stimulation with different quantities of spores. As presented in Fig. 2 , CD11c + MHCII + DCs of naïve mice exposed to the intermediate spores amount (2 × 10 7 LS) upregulated the expression of the co-stimulatory receptors CD40 ( Fig. 2A  and B ) and CD80 (Fig. 2C and D) with regard to PBS treated cells. No effects were observed with plasmid DNA or at a higher (2 × 10 8 ) spore dose, with no detectable fluorescence enhancement for the three tested markers. Also, DCs exposed to a lower (2 × 10 6 ) spore dose enhanced the expression of CD40 but at a reduced intensity with regard to the intermediate spore dose (Fig. 2B ). Inflammatory cytokines (TNF-␣ and IL-6) in cell culture supernatants were detected in elevated values in cells exposed to LPS and the two highest spore concentrations. In contrast, only the sample incubated with 2 × 10 8 LS showed measurable IL-10 values ( Fig. 2D) . Altogether, these results demonstrated that B. subtilis spores can induce migration of murine pro-inflammatory cells and DC activation, which further support the adjuvant effects of spores co-administered with DNA vaccines.
Activation of CD8 + T cell responses and therapeutic anti-tumor protection in mice co-administered with spores and pgDE7h
To demonstrate that B. subtilis spores could also exert adjuvant effects to DNA vaccines, we inoculated mice i.m. with spores (2 × 10 7 ) admixed with a plasmid DNA (pgDE7h) at a dose capable of inducing low CD8 + T cell responses to the HPV-16 E7 oncoprotein and partial therapeutic protection to tumors in mice engrafted with the cells (TC-1) expressing HPV-16 oncoproteins [20] . Coadministration of spores and pgDE7h three days after implantation of TC-1 cells significantly enhanced the IFN-␥ production by E7specific CD8 + T cells compared to mice immunized only with the DNA vaccine or spores separately ( Fig. 3A and B) . Mice inoculated with live spores admixed with the pgDE7h showed higher activation of antigen-specific CD8 + T cells in comparison to mice co-inoculated with heat-killed spores (approximately a two-fold increase). However, co-administration of pgDE7h with both live and killed spores conferred 80% therapeutic anti-tumor immunity, a significantly higher protection values with regard to mice immunized with the same amount of DNA vaccine (40% survival) (Fig. 3C) . Altogether, these results show that B. subtilis spores enhance the pgDE7h-induced CD8 + T cell activation and T cell-mediated antitumor protective immunity.
Dose-dependent adjuvant effects of B. subtilis on the immune responses induced by pgDE7h
The DC activation results suggest that the immune modulation effects of spores are dose dependent. Thus, we tested the effects exert by different number of spores co-delivered with pgDE7h regarding both activation of antigen-specific CD8 + T cells and antigen-specific antibody responses, as well as the anti-tumor protection effects (Fig. 4) . The induction of E7-specific CD8 + T cell responses elicited in mice immunized with pgDE7h reached maximal values two weeks after immunization and was detected with 2 × 10 7 live spores (Fig. 4A) . Accordingly, 80% of the mice coinoculated with 2 × 10 7 spores and pgDE7h remained tumor-free, whereas mice co-administered with 10-fold less or 10-fold more spores showed lower anti-tumor protection levels (Fig. 4B) .
Different results were observed after measurement of the anti-gD and anti-E7 antibody responses. Maximal anti-gD and anti-E7 serum IgG levels were achieved in mice immunized with pgDE7h admixed with 2 × 10 6 spores ( Fig. 4C and D) . Low anti-spores IgG titers were observed only in mice immunized with the higher number of spores (Fig. 4E) . These results suggest that the spore adjuvant effects are dose dependent and require a specific balance of spores and DNA in order to efficiently activate the different arms (CD8 + T lymphocytes or antibody production) of the adaptive immune system.
Discussion
The adjuvant effects of B. subtilis spores have been previously reported using protein-based vaccines and were based on the induction of antigen-specific antibody responses. Nonetheless, no study has been previously performed to investigate the impact of spore administration in the enhancement of immune responses induced by DNA vaccines. In addition, little is known about the potential adjuvant effects of bacterial spores on the cellular immune responses induced by vaccines. In this scenario, our work has investigated both the ability of B. subtilis spores to increase the immune responses induced by a DNA vaccine and demonstrated experimentally that co-administration of spores enhance the induction of cytotoxic responses induced by vaccines. Based on a DNA vaccine encoding the HPV-16 E7 oncoprotein, our results demonstrated that both live and heatkilled spores increased the activation of antigen-specific CD8 + T cells, as well as the functionality of the induced immune response, measured by the vaccine-induced therapeutic antitumor effects. Moreover, we showed that B. subtilis spores activate DCs, recruit pro-inflammatory cells, which is in accordance with the immunomodulatory effects of spores both for purified proteins and DNA vaccines. Finally, our results indicated that, regarding to DNA vaccines, the adjuvant effects of spores, including activation antigen-specific cellular responses and antibody production, are dose-dependent in the murine host, requiring different amounts of spores to induced maximal enhancement of the induced responses.
In our work, B. subtilis spores induced the migration of CD11b + , CD11b + Gr1 + , F4/80 + and F4/80 + Ly6C hi cells, indicating the attraction of neutrophils, immature myeloid cells, macrophages and inflammatory monocytes to the inoculated mice peritoneal cavity. Moreover, B. subtilis spores upregulated expression of CD40 and CD86 co-activation markers in DCs. These results reinforce the application of spores as vaccine adjuvants, since this category of molecules increase the adaptive immune responses usually by activation of cells involved with the innate immune system. This fact is especially relevant for particulate adjuvants, which require uptake by APCs for proper enhancement of adaptive immune responses. For instance, ∼1 m microparticles have been shown to be taken up by APCs, such as DCs, in vivo, leading to migration to the T-cell area of the draining lymph nodes and subsequent maturation [27] . In particular, an efficient DC-mediated endocytosis of B. subtilis spores has been associated with enhanced priming of T cell responses [17] . Thus, spores seem to act as delivery system to APCs and promote direct activation of these cells, particularly for DCs. In fact, DC exposed to B. subtilis spores induced up-regulation of MHC I, MHC II and co-stimulatory molecules, such as CD40, CD25 and CD86, in the absence of exogenous stimulus [28] [29] [30] . The mechanisms related to the spore adjuvant effects have also been attributed to the DCs TLR-mediated signaling, particularly the TLR2 receptor [28, 30] .
The interactions between spores and DCs have been shown to induce a balanced Th1 and Th2 immune response pattern when spores are co-administered with purified proteins and viral particles [17, 28, 29] . Moreover, the adjuvant effects of B. subtilis spores have been reported to occur in a dose-dependent manner [17, 29] . Using diverse antigens as models, the intensity of T cell proliferation and IgA and IgG production, increased proportionally to the concentration of spores co-administered with the antigen [17, 29] . In our study, both expressions of co-stimulatory molecules, CD8 + T cell activation and anti-tumor immunity were achieved with an intermediate spore concentration (2 × 10 7 ). On the other hand, maximal induction of antigen-specific antibody responses was achieved at a lower spore concentration. Notably, a larger amount of spores (2 × 10 8 ) promoted down-regulation or no enhancement of CD80 or CD40 and CD86 in DCs and promoted secretion of IL-10, an immunosuppressive cytokine. Also, administration of the DNA vaccine combined to 2 × 10 8 spores did not increase tumorspecific cellular and antibody responses, neither enhanced the vaccine induced anti-tumor immunity, which may correlate with the in vitro immunosuppressive effects on DCs. Our study suggests, therefore, that B. subtilis spores enhance both humoral and cellular (cytotoxic) immune response induced by DNA vaccines but the adjuvant effects are finely tuned by the amount of co-administered spores. In conclusion, our study describes a novel immunobiological use of B. subtilis spores as particulate adjuvants for DNA vaccines. In particular, our results raise interesting perspectives regarding the enhancement of antigen-specific cytotoxic responses induced by DNA vaccines, thus, representing an alternative tool for anticancer and anti-viral vaccines.
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